AZ, Lilly's BACE Inhibitor Clears Safety Hurdle And Raises Class Hopes
This article was originally published in The Pink Sheet Daily
Executive Summary
All clear from monitoring board means firms will roll into the Phase III portion of the AMARANTH trial.
You may also be interested in...
Eisai Parades Pipeline Before Investors During First US R&D Day
Management highlighted Eisai’s neurology and oncology assets during a Scientific Day in New York, the first formal R&D briefing the Japanese pharma’s US subsidiary has held in more than 20 years operating in the country.
Lilly Back In The BACE Space Following Deal With AstraZeneca
Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.
Lilly Ends Trial Of BACE Inhibitor For Alzheimer’s, But Says Class-Wide Safety Effect Unlikely
With the termination of a Phase II trial of LY2887621, Merck’s MK-8931 leads the race to become the first BACE inhibitor approved for Alzheimer’s, although four other companies have similar candidates in earlier stages of development. Lilly says it may continue to pursue BACE inhibition in Alzheimer’s.